Cambridge Trust’s Repligen RGEN Stock Holding History

Cambridge Trust’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$38K	–	936
2022 Q1	$38K	Buy	+200	New	+$38K	﹤0.01%	573

Other funds holding RGEN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cambridge Trust's RGEN Position: Q2 2022 in Review

Cambridge Trust sold out of Repligen (RGEN) in Q2 2022, closing a stake of 200 shares — an estimated $38K sold.

Cambridge Trust first reported a position in RGEN in Q1 2022 and held it in 1 quarter. The position peaked at $38K in Q1 2022. 404 funds tracked by Wall St. Rank hold RGEN as of Q2 2022.

Cambridge Trust reported no remaining Repligen position as of Q2 2022 after selling out during the quarter.
Cambridge Trust sold 200 Repligen shares in Q2 2022, an estimated $38K.
Cambridge Trust first reported a position in Repligen in Q1 2022 and held it in 1 quarter.
Cambridge Trust's Repligen position peaked at $38K in Q1 2022.
404 funds tracked by Wall St. Rank held Repligen as of Q2 2022.

Based on Cambridge Trust's 13F filing for Q2 2022, filed 16 Aug 2022.